Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Rhea-AI Summary

DBV Technologies released its Half-Year Report on the liquidity contract with ODDO BHF, detailing its assets as of December 31, 2020. The liquidity account held 112,302 shares and €229,086.53, compared to 24,313 shares and €682,454.94 at contract signing in July 2018. During the second half of 2020, 1,180 purchases and 1,136 sales were executed, totaling 517,291 shares bought for €2,005,858.40 and 458,090 shares sold for €1,841,496.60.

Positive

• Increase in liquidity account shares from 24,313 to 112,302.
• Significant trading volume with 517,291 shares purchased.

Negative

• Liquidity account cash decreased from €682,454.94 to €229,086.53.
• Total sales (€1,841,496.60) lower than total purchases (€2,005,858.40).

AMF REGULATED INFORMATION
Montrouge, France, January 29, 2021

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.

As of December 31, 2020, the following assets appeared on the liquidity account:

• 112,302 DBV Technologies shares;
• € 229,086.53.

Upon signing the liquidity contract in July 2018, the following resources appeared on the liquidity account:

• 24,313 DBV Technologies ordinary shares;
• € 682,454.94.

Number of transactions executed during the second half-year of 2020:

• Purchase: 1,180
• Sale: 1,136

Over the same period, the volumes traded represented:

• 517,291 DBV Technologies ordinary shares purchased for €2,005,858.40
• 458,090 DBV Technologies ordinary shares sold for €1,841,496.60

About DBV Technologies 
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

DBV Investor Relations Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com

Attachment

• PDF Version

FAQ

What are the assets reported by DBV Technologies as of December 31, 2020?

DBV Technologies reported 112,302 shares and €229,086.53 in its liquidity account.

How many transactions did DBV Technologies execute in the second half of 2020?

DBV Technologies executed 1,180 purchases and 1,136 sales in the second half of 2020.

What was the total value of shares purchased and sold by DBV Technologies in H2 2020?

In H2 2020, DBV Technologies purchased shares for €2,005,858.40 and sold shares for €1,841,496.60.

What is the significance of the liquidity contract signed by DBV Technologies?

The liquidity contract helps improve the liquidity of DBV Technologies' shares in the market.

How does DBV Technologies' liquidity position compare to when the contract was signed?

As of January 2021, the liquidity account shows a significant reduction in cash from €682,454.94 to €229,086.53.